# INT230-6

Source: https://onco.cc/drugs/int230-6/  
OnCo record `int230-6` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

INT230-6 is an experimental investigational agent whose form is not stated in the registry from Intensity Therapeutics in phase 3 trials for sarcomas, with its target not yet stated publicly.

## Summary

INT230-6 is an investigational agent whose form is not stated in the registry developed by Intensity Therapeutics. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06263231 (A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)), in sarcomas. The largest, NCT06263231, plans to enrol 333 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: not stated (registered as a drug or biological on ClinicalTrials.gov)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of INT230-6: https://clinicaltrials.gov/search?intr=INT230-6

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- companies: [Intensity Therapeutics](https://onco.cc/companies/intensity-therapeutics/)
- trials: [A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)](https://onco.cc/trials/invincible-3/), [Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK](https://onco.cc/trials/nct06358573/)

---
JSON: https://onco.cc/api/v1/entities/int230-6.json